New hope for rare blood cancer: drug combo targets relapsed lymphoma
NCT ID NCT05700448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug sugemalimab to standard chemotherapy can help adults with a rare type of blood cancer (NK/T-cell lymphoma) that has returned or stopped responding to previous treatment. About 150 participants will receive either the new combination or a placebo plus chemo. The goal is to see if the combination delays cancer growth and improves survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Immunotherapy combo may outperform chemo in rare lymphoma
- Engineered donor cells take aim at tough blood cancers in early trial
- Promising combo may slash radiation harm in rare lymphoma
- New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
- New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients